<DOC>
	<DOC>NCT01656265</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of ARQ 197 in hepatocellular carcinoma (HCC) patients treated with daily oral ARQ 197, to determine the recommended dose of ARQ 197 in advanced HCC patients.</brief_summary>
	<brief_title>Study of ARQ 197 in Hepatocellular Carcinoma (HCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Confirmed HCC patients who are resistant to, intolerable to, or rejecting a systemic sorafenib therapy Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 ChildPugh classification A at the time of registration Adequate bone marrow, liver, and renal functions within 14 days prior to registration Prior therapy with a cMet inhibitor (including ARQ 197) Any systemic antitumor treatment or investigational agent within 2 weeks prior to registration. If the treatment/agent was antibody, within 4 weeks Local treatment for malignancy within 4 weeks prior to registration Major surgical procedure within 4 weeks prior to registration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>